Biotech Values

[Bickema]

RVNC - Settle down, Allergan investors. Botox's market share is safe, analysts say

https://www.fiercepharma.com/marketing/settle-down-allergan-investors-botox-s-market-share-safe-analysts

There are a lot of things wrong with this article but it does mention Galderma is potential suitor for Revance

For one, there’s simply “not much evidence that there is a need for more/better toxins in the aesthetic market,”

- Such a dumb comment. I'm pretty sure aesthetic and therapeutic patients would prefer longer duration and less visits to the doc. In this sentence he refers to RT002 as possibly a better toxin, yet later calls it cheap!

Of course, he notes, doctors are in a position to sway their patients if they decide they want to make more money by using cheaper rivals. Patients, however, “are often informed (and would be sensitive to the idea that the doctor uses a cheap alternative to fatten his/her margin)” he figures.

- there is no basis for calling RT002 a cheap alternative. He's inferring that RT002 is inferior like Dysport and Xeomin which it's not.

The much bigger threat, as they see it, would be a long-acting therapy for migraine, where Botox also competes—or a buyout of Revance by a major global player such as Galderma that can better play at Allergan’s level.

- finally a little truth although instead of migraine, which doesn't account for much of botox sales, he should have simply said therapeutic indications.

- Anyway, theres you're Galderma mention :)